Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary) ; Anticoagulants
  • Indications COVID-19 pneumonia; COVID-19 respiratory infection; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors MediciNova

    • Most Recent Events

    • 13 Mar 2023 According to ClinicalTrials.gov record, protocol has been amended as time frame of primary endpoint changed from 7 days to day 28.
    • 13 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
    • 08 Jun 2022 According to a MediciNova media release, the company will discuss the results with the FDA and get their feedback to determine next steps.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top